Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.

导出 OA

翻译打印收藏纠错

作者： Zongwei,Wang ^[1] ; Tuo,Deng ^[2] ; Xingbo,Long ^[3] ; Xueming,Lin ^[4] ; Shulin,Wu ^[5] ; Hongbo,Wang ^[5] ; Rongbin,Ge ^[6] ; Zhenwei,Zhang ^[7] ; Chin-Lee,Wu ^[5] ; Mary-Ellen,Taplin ^[7] ; Aria F,Olumi ^[8]

作者单位： Department of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.;Department of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. ^[1] Department of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.;Department of Urology, Minimally Invasive Surgery center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou, Guangdong, China. ^[2] Department of Urology, Union Medical College, Beijing, China. ^[3] Department of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.;Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. ^[4] Department of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. ^[5] Department of Pathology, University of Massachusetts Medical School, Worcester, MA, United States of America. ^[6] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America. ^[7] Department of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America. ^[8]